Capital International Ltd. CA Has $15.75 Million Stock Position in Amgen Inc. $AMGN

Capital International Ltd. CA lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 81.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 55,813 shares of the medical research company’s stock after purchasing an additional 25,071 shares during the period. Capital International Ltd. CA’s holdings in Amgen were worth $15,750,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the stock. Sequoia Financial Advisors LLC lifted its stake in shares of Amgen by 2.3% during the third quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock valued at $45,334,000 after acquiring an additional 3,619 shares during the period. Davis Capital Management bought a new stake in Amgen during the 3rd quarter worth about $1,841,000. D.A. Davidson & CO. boosted its stake in shares of Amgen by 2.6% in the 3rd quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock valued at $68,590,000 after purchasing an additional 6,222 shares during the last quarter. Global Wealth Management Investment Advisory Inc. raised its stake in shares of Amgen by 56.2% during the third quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock worth $3,684,000 after buying an additional 4,699 shares during the last quarter. Finally, Jones Financial Companies Lllp boosted its stake in Amgen by 18.2% in the third quarter. Jones Financial Companies Lllp now owns 39,778 shares of the medical research company’s stock valued at $10,888,000 after acquiring an additional 6,115 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

AMGN has been the subject of a number of analyst reports. Morgan Stanley lifted their price objective on Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 4th. Weiss Ratings reiterated a “buy (b)” rating on shares of Amgen in a report on Monday, December 29th. BMO Capital Markets raised their price objective on Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 3rd. Erste Group Bank upgraded shares of Amgen from a “hold” rating to a “buy” rating in a report on Friday, December 5th. Finally, UBS Group upped their target price on shares of Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Amgen has a consensus rating of “Hold” and an average price target of $354.17.

Amgen Price Performance

Shares of AMGN opened at $376.97 on Tuesday. The company has a market cap of $203.21 billion, a price-to-earnings ratio of 26.49, a PEG ratio of 3.67 and a beta of 0.45. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The company’s fifty day simple moving average is $354.21 and its 200 day simple moving average is $323.38. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. During the same period in the previous year, the business earned $5.31 EPS. Amgen’s revenue for the quarter was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Friday, May 15th. Amgen’s payout ratio is currently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.